乳腺癌患者血清中可溶性白介素-2受体测定的临床意义探讨

Studies on Serum SIL-2R Levels in Patients With Breast Cancer

本研究应用双抗体夹心酶联免疫吸附（ELISA）法同批对50例乳腺癌患者，30例乳腺腺瘤患者及40例正常人的血清可溶性白介素－2受体（SolubleInterleukin－2Receptor，SIL－2R）进行了检测。结果显示：乳腺癌患者的血清SIL－2R水平明显高于乳腺腺瘤患者及正常对照组，统计学上具有极显著差异（P＜0．01）；乳腺癌根治术后20天的SIL－2R水平较术前明显下降，与正常人群对照无明显差异（P＞0．05），乳腺癌患者的术前SIL-2R水平与临床分期关系密切，Ⅲ期患者明显高于I、Ⅱ期者（P＜0.01），而与病理类型无明显关系。上述结果提示：血清SIL－2R测定可作为鉴别乳腺癌和乳腺良性肿物及判断乳腺癌病情、观察疗效的一项有价值的参考指标。

Using the method of sanwich ELISA, we study the mean levels of serum SIL2R in the patients with breast cancer. At the same time, we also detect 30 patiants with breast benign diease and 40 of norma lindividuals. The result shows that the serum SIL-2R of breast cancer much higher than that of breast benign diease and the controls (P<0.01). Serum SIL-2R level decrease significantg at 20 days after radical surgery for breast cancer, with no remarkably difference to the healthy (P>0. 05 ) but the serum SIL-2R of 7 days after radical surgery for breast cancer similer that of pre-operater. The serum SIL-2R leavel in relative to the clinical stage of berast cacer, butisnt relative to the pathology. It can be concluded that serum SIL-2R assay is a new biological marker for the assessmert of the stage, the sponre to medical intervention and the prognosis in breast cancer.